Multi-target drug conjugate and use thereof for cancer treatment

Abstract

Provided is a cancer targeting construct comprising a first end and a second end, the first end comprising an IL-13 targeting protein, or an IL-13RA2 binding mutant or fragment of IL-13, and the second end comprising an eA5 targeting protein, or an EphA2, EphA3 and EphB2 binding mutant or fragment of eA5, and an effector molecule coupled to said first end and/or said second end, wherein said construct is a fusion protein and/or a covalent conjugate. Also provided is a method of treating cancer (e.g., breast cancer) in a subject in need thereof, comprising administering to said subject a construct as taught herein, or composition comprising the construct, in a treatment effective amount.

Dependencies are inferred from the claim text.